



# THE LAB+BEYOND

JULY 24-28 / CHICAGO, IL / USA



[Print this Page for Your Records](#)

[Close Window](#)

**Control/Tracking Number:** 22-A-289-AACC

**Activity:** Abstract

**Current Date/Time:** 2/22/2022 1:16:39 AM


## Identification of clinical common invasive fungal disease via a multi-channel qPCR melting curve analysis

**Author Block:** [Z. Wang](#), S. Li, Y. Zhang, X. Yan, W. Yao, H. Wang. *Dynamiker Sub-Center of Beijing Key Laboratory for Mechanisms Research and Precision Diagnosis of Invasive Fungal Disease, Tianjin, China,*

### Abstract:

**Background** Quantitative polymerase chain reaction (qPCR) is a routinely used method for the detection and quantitation of gene expression in real-time. Multiplex qPCR requires the use of probe-based assays, in which each probe is labeled with a unique fluorescent dye, resulting in different observed signals for each assay. The signal from each dye is used to detect each target separately in the same tube or well. The availability to multiplex therefore allows the measurement of the expression levels of several targets or genes of interest quickly. Based on the above principles, a series of kits including MycoMDx *Aspergillus* PCR Assay Kit, MycoMDx *Mucorales* PCR Assay Kit, MycoMDx *Pneumocystis Jiroveci* PCR Assay Kit, and MycoMDx *Talaromyces marneffei* PCR Assay Kit were developed. (Table 1). **Methods** In the present study, we evaluated the clinical performance of the MycoMDx *Aspergillus* PCR Assay Kit, MycoMDx *Mucorales* PCR Assay Kit, MycoMDx *Pneumocystis jiroveci* PCR Assay Kit and MycoMDx *Talaromyces marneffei* PCR Assay Kit (CE- approved), which includes 153 clinical samples (Positive samples 78; Negative samples 75). The above PCR detection reagents were developed and produced by Dynamiker Biotechnology (Tianjin) Co., Ltd. **Results** The sensitivity and specificity of the MycoMDx *Aspergillus* PCR Assay Kit, MycoMDx *Mucorales* PCR Assay Kit, MycoMDx *Pneumocystis jiroveci* PCR Assay Kit and MycoMDx *Talaromyces marneffei* PCR Assay Kit were 92.0% and 97.1%, 91.7% and 100.0%, 90.5% and 97.7%, 95.0% and 97.1%, respectively. **Conclusions** The *Aspergillus* PCR Assay Kit, MycoMDx *Mucorales* PCR Assay Kit, MycoMDx *Pneumocystis jiroveci* PCR Assay Kit, and MycoMDx *Talaromyces marneffei* PCR Assay Kit have a great clinical value. Especially, the *Aspergillus* PCR Assay Kit can fast and accurate identification of clinically relevant *Aspergillus* species (*A. fumigatus*, *A. flavus*, *A. terreus*, and *A. niger*) directly in clinical samples (BALF, serum).

Table 1 Development of four detection kits

PCR assay	Detecting target	Sample type	Kits	Amplification curve
1 MycoMDx <i>Aspergillus</i> PCR Assay	<i>Aspergillus</i> <i>Aspergillus</i> <i>Aspergillus terreus</i> <i>Aspergillus niger</i> <i>Aspergillus fumigatus</i>	Serum, BALF		
2 MycoMDx <i>Mucorales</i> PCR Assay	<i>Rhizopus</i> spp. Minor spp. <i>Lincolnomyces</i> spp. <i>Cunninghamella</i> sp. sp. <i>Rhizoglyphus</i> spp.	Biopsy, serum and BALF		
3 MycoMDx <i>Pneumocystis</i> <i>jiroveci</i> PCR assay	<i>Pneumocystis</i> <i>jiroveci</i>	BALF		
4 MycoMDx <i>Talaromyces</i> <i>marneffei</i> PCR Assay	<i>Talaromyces</i> <i>marneffei</i>	Serum		

**Topic (Complete):** Molecular Diagnostics ; Microbiology and Infectious Diseases

**Related Division (Complete):** Molecular Pathology Division ; Clinical Translational Science Division ; Clinical and Diagnostic Immunology Division

**Oral Presentation (Complete):** None selected

**Division Awards (Complete):**

**Molecular Pathology Division Abstract Award :** True

**Personalized Medicine Division Abstract Award :** True

**I have read and understand the eligibility requirements for any awards I have selected. (required) :** True

**Additional Awards (Complete):**

**I wish to be considered for the NACCCA Travel Grant Award :** True

**Attached Files:** No Files Attached

**Status:** Complete

[AACC | AACC Annual Scientific Meeting](#)

900 Seventh Street, NW, Suite 400  
Washington, DC 20001

If you need technical support:

[OASIS Helpdesk](#) or 217-398-1792

 Feedback

Powered by [cOASIS](#), The Online Abstract Submission and Invitation System <sup>SM</sup>  
© 1996 - 2022 [CTI Meeting Technology](#). All rights reserved. [Privacy Policy](#).